Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-380135 in Adults With Schizophrenia, Bipolar Disorder, or Major Depressive Disorder
NCT07549581Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SEP-380135 in schizophrenia, bipolar disorder (BD) and major depressive disorder (MDD) (5 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Adverse Events, Columbia-Suicide Severity Rating Scale and 27 more. Started Nov 2024; status: completed.
02
Drugs
SEP-380135
03
Conditions
schizophreniabipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07549581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549581.